These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 29804389)

  • 21. [Recent advances in the treatment of hepatitis C in 2016].
    Luo BF; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):175-180. PubMed ID: 28482403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New perspectives for preventing hepatitis C virus liver graft infection.
    Felmlee DJ; Coilly A; Chung RT; Samuel D; Baumert TF
    Lancet Infect Dis; 2016 Jun; 16(6):735-745. PubMed ID: 27301929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.
    Iacobellis A; Andriulli A
    Expert Opin Pharmacother; 2009 Aug; 10(12):1929-38. PubMed ID: 19563272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Interferon-Free, Direct-Acting Antivirals Treatment for Japanese Patients with Chronic Hepatitis C Infection and Chronic Kidney Disease.
    Atsukawa M; Kondo C; Kawano T; Okubo T; Arai T; Nakagawa-Iwashita A; Itokawa N; Iwakiri K
    J Nippon Med Sch; 2021 Jun; 88(3):163-170. PubMed ID: 33692289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease.
    Lens S; Mariño Z; Forns X
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S197-205. PubMed ID: 25458782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
    Teriaky A; Reau N
    Clin Liver Dis; 2015 Nov; 19(4):591-604, v. PubMed ID: 26466649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
    Everson GT
    Rev Gastroenterol Disord; 2004; 4 Suppl 1():S31-8. PubMed ID: 15184823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
    Zhu F; Zhang QY; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):173-174. PubMed ID: 29807402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvir.
    Borentain P; Colson P; Darque A; Gérolami R
    Liver Int; 2015 Jun; 35(6):1776. PubMed ID: 25619265
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Direct-Acting Antiviral Agents Can Be Hepatotoxic in Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis.
    Ou P; Li F; Chen J
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1669-1671. PubMed ID: 27329403
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
    Ippolito AM; Milella M; Messina V; Conti F; Cozzolongo R; Morisco F; Brancaccio G; Barone M; Santantonio T; Masetti C; Tundo P; Smedile A; Carretta V; Gatti P; Termite AP; Valvano MR; Bruno G; Fabrizio C; Andreone P; Zappimbulso M; Gaeta GB; Napoli N; Fontanella L; Lauletta G; Cuccorese G; Metrangolo A; Francavilla R; Ciracì E; Rizzo S; Andriulli A
    Dig Liver Dis; 2017 Sep; 49(9):1022-1028. PubMed ID: 28487083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel.
    Viganò M; Perno CF; Craxì A;
    Dig Liver Dis; 2017 Jul; 49(7):731-741. PubMed ID: 28456519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
    Sorbera MA; Friedman ML; Cope R
    J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical timing and benefit of antiviral treatment for hepatitis C].
    Chen LC; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):164-169. PubMed ID: 28482401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.